BRAF and cancer: Furthermore, the clonogenic assay results showed a 69.67% decrease in cell proliferation only in A375 cells treated with eCas12f1-BRAF (Fig. 5i, k), while no significant difference was observed in the HEK293T cells (Fig. 5h, j), demonstrating that eCas12f1 can be used effectively and safely in cancer therapy.